Analysts Set Vivos Therapeutics, Inc. (NASDAQ:VVOS) Price Target at $4.92

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $4.9167.

Several research analysts have recently commented on VVOS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, October 8th. Ascendiant Capital Markets decreased their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, December 3rd. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Finally, HC Wainwright initiated coverage on Vivos Therapeutics in a research report on Monday, November 17th. They set a “buy” rating and a $7.00 target price for the company.

Vivos Therapeutics Price Performance

Shares of VVOS opened at $2.22 on Tuesday. The company’s 50-day moving average is $2.22 and its 200-day moving average is $3.43. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78. The firm has a market capitalization of $19.96 million, a PE ratio of -1.25 and a beta of 6.89. Vivos Therapeutics has a fifty-two week low of $1.92 and a fifty-two week high of $7.95.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Wednesday, November 19th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%.The company had revenue of $6.78 million for the quarter, compared to the consensus estimate of $4.49 million. Equities analysts forecast that Vivos Therapeutics will post -1.79 EPS for the current year.

Institutional Investors Weigh In On Vivos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in shares of Vivos Therapeutics during the 2nd quarter worth approximately $65,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics during the 2nd quarter valued at $220,000. Finally, Connective Capital Management LLC purchased a new position in Vivos Therapeutics during the third quarter worth about $620,000. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.